Pear Therapeutics Receives FDA Breakthrough Designation for reSET-A

By Colin Kellaher

Pear Therapeutics Inc. on Monday said the U.S. Food and Drug Administration granted breakthrough-device designation for its reSET-A prescription digital therapeutic product candidate designed for the treatment of alcohol use disorder.

The Boston company, which in June unveiled plans to go public through a merger with blank-check company Thimble Point Acquisition Corp., said reSET-A potentially expands its addiction franchise, which includes FDA-approved products to treat substance and opioid use disorders.

The FDA's breakthrough-devices program aims to expedite the development and review of technology that offers significant advantages over existing approved products.

Write to Colin Kellaher at [e-mail]

(END) Dow Jones Newswires

11-22-21 0850ET